Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-Aza-2′-deoxycytidine

Cancer

Volumn 106, Issue 11, 2006, Pages 2514-2525

  Arai, Makoto ^a   Yokosuka, Osamu ^a   Hirasawa, Yuichi ^a   Fukai, Kenichi ^a   Chiba, Tetsuhiro ^a   Imazeki, Fumio ^a   Kanda, Tatsuo ^a   Yatomi, Mari ^a   Takiguchi, Yuichi ^a   Seki, Naohiko ^a   Saisho, Hiromitsu ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

5 aza 2 deoxycytidine; Cancer cell lines; Gene expression; Microarray

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; DNA; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CELL METABOLISM; CONTROLLED STUDY; CYTOSKELETON; DEMETHYLATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

AZACITIDINE; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 33646894314     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21905     Document Type: Article

References (31)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
2. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA. 1993;90:11995-11999.
3. Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene. 2001;20:3156-3165.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-167.
5. Baylin SB. Reversal of gene silencing as a therapeutic target for cancer-roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp. 2004;259:226-233; discussion, 234-227, 285-228.
6. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948-3956.
7. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483-5495.
8. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957-2964.
9. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
10. Ferguson AT, Vertino PM, Spitzner JR, et al. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem. 1997;272:32260-32266.
11. Fukai K, Yokosuka O, Chiba T, et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res. 2003;63:8674-8679.
12. Chiba T, Yokosuka O, Fukai K, et al. Identification and investigation of methylated genes in hepatoma. Eur J Cancer. 2005;41:1185-1194.
13. Arai M, Yokosuka O, Chiba T, et al. Gene expression profiling reveals the mechanism and pathophysiology of mouse liver regeneration. J Biol Chem. 2003;278:29813-29818.
14. Otsuka M, Arai M, Mori M, et al. Comparing gene expression profiles in human liver, gastric, and pancreatic tissues using full-length-enriched cDNA libraries. Hepatol Res. 2003;27:76-82.
15. Arai M, Yokosuka O, Fukai K, et al. Gene expression profiles in liver regeneration with oval cell induction. Biochem Biophys Res Commun. 2004;317:370-376.
16. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a Web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics. 2004;20:578-580.
17. Lavelle D, DeSimone J, Hankewych M, et al. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003;27:999-1007.
18. Ferguson AT, Lapidus RG, Baylin SB, et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995;55:2279-2283.
19. Stone AR, Bobo W, Brat DJ, et al. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol. 2004;165:1151-1161.
20. Otterson GA, Khleif SN, Chen W, et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene. 1995;11:1211-1216.
21. Tada M, Yokosuka O, Fukai K, et al. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J Hepatol. 2005;42:511-519.
22. Endo K, Ueda T, Ueyama J, et al. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol. 2000;31:558-565.
23. Kramer RH, Shen X, Zhou H. Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev. 2005;24:35-45.
24. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002;8:385-392.
25. Sakamoto Y, Mafune K, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol. 2000;17:237-243.
26. Giganti A, Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res. 2003;5:511-525.
27. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
28. Missiaglia E, Donadelli M, Palmieri M, et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene. 2005;24:199-211.
29. Narimatsu T, Tamori A, Koh N, et al. p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection. Intervirology. 2004;47:26-31.
30. Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem. 2002;277:22573-22580.
31. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64:4277-4285.